PMID- 36871874
OWN - NLM
STAT- MEDLINE
DCOM- 20230410
LR  - 20230411
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 198
DP  - 2023 Apr
TI  - Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic 
      review and meta-analysis.
PG  - 110605
LID - S0168-8227(23)00080-3 [pii]
LID - 10.1016/j.diabres.2023.110605 [doi]
AB  - OBJECTIVES: To investigate the efficacy and safety of oral semaglutide 7 and 
      14 mg, the only orally delivered glucagon-like peptide-1 (GLP-1) receptor agonist 
      tablet approved for type 2 diabetes mellitus (T2DM) patients. METHODS: Search 
      several databases for randomized controlled trials (RCTs) of oral semaglutide in 
      patients with T2DM from inception through May 31, 2021. The primary outcomes 
      included change from baseline in hemoglobin A1c (HbA1c) and body weight. Risk 
      ratios (RR), mean differences (MD), and 95% confidence intervals (CI) were 
      calculated to evaluate the outcomes. RESULTS: This meta-analysis included 11 RCTs 
      with a total of 9821 patients. Compared with placebo, semaglutide 7 and 14 mg 
      reduced HbA1c by 1.06% (95% CI, 0.81-1.30) and 1.10% (95% CI, 0.88-1.31), 
      respectively. While in comparison with other antidiabetic agents, semaglutide 7 
      and 14 mg reduced HbA1c by 0.26% (95% CI, 0.15-0.38) and 0.38% (95%CI, 
      0.31-0.45). Both doses of semaglutide could significantly reduce body weight. 
      Semaglutide 14 mg did increase the incidence of medication discontinuation and 
      gastrointestinal events (nausea, vomiting and diarrhea). CONCLUSION: Once-daily 
      semaglutide 7 and 14 mg can significantly lowered HbA1c and body weight in 
      patients with T2DM, and this effect increases with dose. Significantly, more 
      gastrointestinal events occurred with semaglutide 14 mg.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Li, Aihua
AU  - Li A
AD  - Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 
      510282, Guangdong, China.
FAU - Su, Xiaorong
AU  - Su X
AD  - Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 
      510282, Guangdong, China.
FAU - Hu, Shanshan
AU  - Hu S
AD  - Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai 200080, China. Electronic address: 
      h1435086126@163.com.
FAU - Wang, Yong
AU  - Wang Y
AD  - Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 
      510282, Guangdong, China; Laboratory of Research of New Chinese Medicine, 
      Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong, 
      China. Electronic address: yongwh2005@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20230305
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 53AXN4NNHX (semaglutide)
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
SB  - IM
MH  - Humans
MH  - Glycated Hemoglobin
MH  - Treatment Outcome
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Hypoglycemic Agents/adverse effects
MH  - Body Weight
MH  - Glucagon-Like Peptide-1 Receptor/agonists
OTO - NOTNLM
OT  - Meta-analysis
OT  - Oral semaglutide
OT  - Systematic review
OT  - Type 2 diabetes mellitus
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/03/06 06:00
MHDA- 2023/04/10 06:42
CRDT- 2023/03/05 19:33
PHST- 2022/02/22 00:00 [received]
PHST- 2022/09/24 00:00 [revised]
PHST- 2023/02/28 00:00 [accepted]
PHST- 2023/04/10 06:42 [medline]
PHST- 2023/03/06 06:00 [pubmed]
PHST- 2023/03/05 19:33 [entrez]
AID - S0168-8227(23)00080-3 [pii]
AID - 10.1016/j.diabres.2023.110605 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2023 Apr;198:110605. doi: 10.1016/j.diabres.2023.110605. 
      Epub 2023 Mar 5.